600572 Zhejiang Conba Pharmaceutical
- 5.11
- -0.10-1.92%
Zhejiang Conba Pharmaceutical News
Guoyuan Securities released a research report on April 24 stating that it gave Kangenbei (600572.SH) a purchase rating. The main reasons for the rating include: 1) Performance growth is in line with expectations, and the overall business trend continues t
SDIC Securities released a research report on April 24 stating that it gave Kangenbei (600572.SH) a purchase rating and the target price was 7.00 yuan. The main reasons for the rating include: 1) the performance is in line with expectations, and the busin
Conn Bay (600572) 2023 Annual Report Review: Main business focuses on accelerating steady growth in performance
Kangenbei (600572): Steady growth in performance, accelerated development of traditional Chinese medicine health business
Conn Bay (600572): Steady growth in performance, “improving quality, efficiency, and heavy return” promotes high corporate dividends
Guojin Securities released a research report on April 22 stating that it gave Kangenbei (600572.SH) an increase in its holdings. The main reasons for the rating include: 1) product structure optimization, healthy growth in the core business of Traditional
Connbey (600572): Stable and progressive performance in 2023, “two wings in one” are poised to break through again
Kangenbei (600572): Adhere to the “Big Variety, Big Brand” Strategy to Improve Quality, Increase Efficiency, and Value Returns
Conn Bay (600572): Focus on the main business strategy, and have achieved remarkable results in brand building
Conn Bay (600572): Big brands, big varieties, outstanding performance, R&D empowers future development
Guojin Securities released a research report on April 9 stating that Connbe (600572.SH) was given an increase in holdings rating, and the target price was 5.40 yuan. The main reasons for the rating include: 1) the company uses modern traditional Chinese m
In-depth research by Kangenbei (600572): The growth trend of key varieties with mixed reform to improve quality and efficiency is good
Connbay (600572): Performance remains stable, core product volume maintains rapid profit growth
Connbay (600572): Performance remains stable, core product volume maintains rapid profit growth
Connbay (600572): Performance is in line with expectations, and the Chinese medicine health business is growing rapidly
Connbay (600572) 2023 Third Quarter Report Review: Steady Growth in Performance, Continued Release of Core Products
Connbay (600572): Performance is in line with expectations, and the main Chinese medicine health industry has outstanding performance
Connbey (600572): Focus on the rebirth of traditional Chinese medicine, a health veteran pharmaceutical company
Cornbay (600572): High performance growth, significant increase in endogenous motivation
Connbey (600572) 2023 Semi-Annual Report Review: Focus on the Main Business Brand and Highlight Forest Advantages
Analysis
Price Target
No Data
